Table 2.
Effects of piroxicam and deracoxib combination on cell cycle phase distribution of CMT-U27 cells. Data are expressed as mean values ± standard error of means shown with *P < 0.05 versus control group.
| Drug concentrations | % G0/G1 | % S | % G2/M |
|---|---|---|---|
| Control | 63.8 ± 2.11 | 22.48 ± 1.52 | 13.72 ± 1.50 |
| Piroxicam + deracoxib (50 + 50 μM) | 67.4 ± 3.04 | 19.97 ± 1.63 | 12.63 ± 1.26 |
| Piroxicam + deracoxib (100 + 100 μM) | 64.53 ± 2.51 | 22.27 ± 1.22 | 13.2 ± 1.10 |
| Piroxicam + deracoxib (250 + 250 μM) | 69.58 ± 3.50 | 17.75 ± 1.45 | 12.67 ± 0.76 |
| Piroxicam + deracoxib (500 + 500 μM) | 72.2 ± 2.17 | 19.95 ± 1.12 | 7.85 ± 1.51 |
| Piroxicam + deracoxib (1000 + 1000 μM) | 89.95 ± 3.35* | 8.27 ± 1.81* | 1.78 ± 0.68* |